Targeted therapy: Overcoming drug resistance with clinical cancer genome

Expert Review of Anticancer Therapy

Volumn 12, Issue 7, 2012, Pages 861-864

  Ziogas, Demosthenes E ^a,b   Katsios, Christos S ^a   Tzaphlidou, Margaret ^c   Roukos, Dimitrios H ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

cancer; clinical genome; DNA RNA sequencing; mutations; NGS; precision medicine; targeted drugs; transcriptome

Indexed keywords

EVEROLIMUS; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; VEMURAFENIB;

BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; GENE FUNCTION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOME; HIGH THROUGHPUT SEQUENCING; HUMAN; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; REVIEW; RNA SEQUENCE; SEQUENCE ANALYSIS; STOMACH CANCER; TUMOR GENE; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENES, NEOPLASM; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84864625465     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.68     Document Type: Review

References (23)

1. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol. Biol. 795, 1-34 (2012).
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011).
4. Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 16(6), 800-810 (2011).
5. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
6. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, Phase 3 trial. Lancet 379(9816), 633-640 (2012).
7. Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012).
8. Baselga J, Campone M, Piccart M. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520-529 (2012).
9. Stratton MR. Exploring the genomes of cancer cells: Progress and promise. Science 331(6024), 1553-1558 (2011).
10. Ideker T, Krogan NJ. Differential network biology. Mol. Syst. Biol. 8, 565 (2012).
11. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N. Engl. J. Med. 366(6), 489-491 (2012).
12. Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am. J. Clin. Pathol. 136(4), 527-539 (2011).
13. Phimister EG, Feero WG, Guttmacher AE. Realizing genomic medicine. N. Engl. J. Med. 366(8), 757-759 (2012).
14. Ding L, Ley TJ, Larson De et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382), 506-510 (2012).
15. Ross-Innes CS, Stark R, Teschendorff AE et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381), 389-393 (2012).
16. Roychowdhury S, Iyer MK, Robinson DR et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci. Transl. Med. 3(111), 111ra121 (2011).
17. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
18. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
19. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
20. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: A promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
21. Katsios C, Roukos DH. Individual genomes and personalized medicine: Life diversity and complexity. Personalized Med. 7(4), 347-350 (2010).
22. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
23. Roukos DH. Next-generation, genome sequencing-based biomarkers: Concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).